37 D. Rimm - Analytic approaches to understanding PD-L1 expr...
38 N. Normanno - Liquid biopsies: facts and myths.
39 F. Hirsch - Next Generation Sequencing: is there any clin...
40 G. Bronte - Mechanisms of acquired resistance to EGFR TKI...
42 L. Landi - Current treatment algorithms for EGFR-mutated...
43 B. Oyan-Uluc - Current treatment algorithms for ROS1+ pat...
44 V. Papadimitrakopoulou - Targeted therapy beyond EGFR, AL...
46 E. Linardou - Lorlatinib in ALK+ NSCLC: the next step.
47 S. Agelaki - Immunotherapy in 1st line NSCLC: from trials...
48 F. Grossi - I O combination in 1st line NSCLC - practice...
49 S. Gettinger - Immunotherapy in oncogene driven mNSCLC.
50 D. Rimm - Immunotherapy biomarkers beyond PD-L1.
51 R. Pirker - The role of targeted therapies in early stage...